Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1241-1260 of 1,782 trials

Hepatocellular Carcinoma: Durvalumab and Tremelimumab Study

We are comparing two treatment methods for patients with liver cancer to see if combining immune therapy with chemotherapy improves outcomes. The study will assess effectiveness, safety, and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Emergency Tracheal Intubation: New Optimization Strategy

We are studying a new method for emergency tracheal intubation to see if it reduces complications in adult patients. This approach combines medication and ventilation techniques to improve patient safety during emergencies.

Respiratory Distress>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard Medicines

Preventing Pancreatic Fistulas: Botulinum Toxin Injection Study

We are studying whether botulinum toxin injections can help prevent complications after pancreatic surgery in patients undergoing distal pancreatectomy. This trial aims to improve recovery and reduce the risk of serious postoperative issues.

Pancreatic Fistula≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Staphylococcus Aureus Bloodstream Infections: Dalbavancin Study

We are testing a single dose of intravenous Dalbavancin against standard antibiotics for patients with bloodstream infections. The goal is to see if Dalbavancin is as effective and to evaluate its impact on recovery and quality of life.

Catheter-Related Bloodstream Infections3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Squamous Cell Carcinoma: Cetuximab with or without Paclitaxel

We are studying the effectiveness of cetuximab alone or with paclitaxel for patients with recurrent head and neck cancer after previous treatment. The goal is to see how these options affect survival and quality of life.

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Avapritinib: Continued Access for Previous Study Participants

We are offering ongoing access to avapritinib for adults who benefited from it in a prior study. This trial also aims to evaluate the long-term safety of the treatment.

Systemic Mastocytosis6-12 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Myotonia Treatment: Mexiletine PR vs. Mexiletine IR

We are comparing two forms of mexiletine to see which one is safer and more effective for adults with non-dystrophic myotonias. This study aims to improve treatment options for conditions like myotonia congenita and paramyotonia congenita.

Myotonic DystrophyNon-Dystrophic Myotonias6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Multiple Myeloma: Isatuximab with Novel Agents

We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Hemoptysis Treatment: TXA vs. Terlipressin

We are studying whether inhaled tranexamic acid or terlipressin can help control coughing up blood in hospitalized patients. The goal is to see if these treatments work better than a placebo in managing this serious condition.

Coughing Up Blood (Hemoptysis)Confirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInternal MedicinePulmonology

Cancer Pain Management: Paracetamol with Opioids

We are studying whether stopping paracetamol affects pain control in patients using strong opioids for cancer-related pain. We also want to see if this change impacts side effects and overall patient satisfaction.

Metastatic Cancer≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineOncology

Nephrogenic Diabetes Insipidus: Amiloride Treatment Study

We are investigating whether amiloride can help patients with nephrogenic diabetes insipidus caused by lithium treatment for bipolar disorder. The study looks at its effects on urine concentration, thirst, and quality of life.

Bipolar Disorder with Lithium Treatment>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNephrologyPsychiatry

Septic Shock: Ivabradine for Heart Rate Control

We are studying whether Ivabradine can help control heart rate and improve survival in patients with septic shock. This trial compares the medication to a placebo to assess its effectiveness.

Septic Shock>2 yearsConfirmation phase (III)Standard MedicinesCardiologyInfectious DiseasesInternal Medicine

Mitapivat for Children with Pyruvate Kinase Deficiency

We are studying whether Mitapivat can help increase hemoglobin levels in children with Pyruvate Kinase Deficiency who do not receive regular blood transfusions. This trial compares the treatment to a placebo to assess its effectiveness.

Pyruvate Kinase Deficiency Anemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteHematologyPediatrics

Alzheimer's Disease: Donepezil vs. Non-Drug Treatment

We are studying whether daily donepezil can improve thinking skills in people with Alzheimer's compared to usual non-drug care. We will also look at its effects on quality of life and other clinical measures.

Alzheimer's Disease6-12 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesNeurology

Prostate Cancer: Apalutamide with Surgery

We are studying if adding apalutamide to standard hormone therapy helps men with high-risk prostate cancer after surgery. The goal is to see if this combination improves cancer control compared to hormone therapy alone.

Metastatic Prostate Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Infection Prevention in Joint Replacement: PREVENT-iT Study

We are studying whether different irrigation solutions and local vancomycin can lower the risk of infections after hip or knee joint replacement surgeries. This research aims to improve patient outcomes and reduce the need for additional surgeries.

Total Joint Replacement SurgeryConfirmation phase (III)Standard MedicinesInfectious DiseasesOrthopedics and Traumatology

Metoprolol for Heart Health in Duchenne Muscular Dystrophy

We are studying whether metoprolol can help prevent heart issues in boys aged 8-17 with Duchenne Muscular Dystrophy. This trial will compare its effects to a placebo alongside standard heart care.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyNeurology

Rituximab for Children with Nephrotic Syndrome

We are studying whether early treatment with rituximab helps children with idiopathic nephrotic syndrome stay in remission longer than those receiving a placebo. This trial aims to improve treatment strategies for this condition.

Nephrotic Syndrome>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesInternal MedicineNephrology

Marfan Syndrome: Valsartan for Aortic Health

We are studying whether valsartan can slow down aortic root dilatation in children and young adults with Marfan syndrome. The trial will measure changes in aortic size and related health outcomes.

Marfan SyndromeLoeys-Dietz SyndromeEhlers-Danlos Syndrome>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Levosimendan Therapy for Low Ejection Fraction Takotsubo Syndrome

We are studying whether levosimendan can help improve heart function and reduce serious health risks in patients with Takotsubo syndrome. This trial compares the medication to a placebo to see if it makes a difference.

Takotsubo Syndrome1-2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteCardiologyInternal Medicine